Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Akram Alwithenani"'
Autor:
Zaid Taha, Mathieu Joseph François Crupi, Nouf Alluqmani, Duncan MacKenzie, Sydney Vallati, Jack Timothy Whelan, Faiha Fareez, Akram Alwithenani, Julia Petryk, Andrew Chen, Marcus Mathew Spinelli, Kristy Ng, Judy Sobh, Christiano Tanese de Souza, Priya Rose Bharadwa, Timothy Kit Hin Lee, Dylan Anthony Thomas, Ben Zhen Huang, Omar Kassas, Joanna Poutou, Victoria Heather Gilchrist, Stephen Boulton, Max Thomson, Ricardo Marius, Mohsen Hooshyar, Scott McComb, Rozanne Arulanandam, Carolina Solange Ilkow, John Cameron Bell, Jean-Simon Diallo
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract Targeted antineoplastic immunotherapies have achieved remarkable clinical outcomes. However, resistance to these therapies due to target absence or antigen shedding limits their efficacy and excludes tumours from candidacy. To address this l
Externí odkaz:
https://doaj.org/article/f45d398fc89f455a93faf9739ef489c7
Autor:
Akram Alwithenani, Rozanne Arulanandam, Boaz Wong, Marcus M. Spinelli, Andrew Chen, Glib Maznyi, Victoria H. Gilchrist, Tommy Alain, Jean-Simon Diallo
Publikováno v:
Viruses, Vol 16, Iss 6, p 920 (2024)
Oncolytic virotherapy, using viruses such as vesicular stomatitis virus (VSVΔ51) and Herpes Simplex Virus-1 (HSV-1) to selectively attack cancer cells, faces challenges such as cellular resistance mediated by the interferon (IFN) response. Dimethyl
Externí odkaz:
https://doaj.org/article/e68341392f4b4cbdac032deca9f1be17
Autor:
Akram Alwithenani, Zaid Taha, Max Thomson, Andrew Chen, Boaz Wong, Rozanne Arulanandam, Jean-Simon Diallo
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Immunotherapy and specifically oncolytic virotherapy has emerged as a promising option for cancer patients, with oncolytic herpes simplex virus-1 (oHSV-1) expressing granulocyte macrophage colony stimulating factor being the first OV to be approved b
Externí odkaz:
https://doaj.org/article/9681e9f44e5e4063a33fb68404dc3744
Autor:
Akram Alwithenani, Drew Bethune, Mathieu Castonguay, Arik Drucker, Gordon Flowerdew, Marika Forsythe, Daniel French, John Fris, Wenda Greer, Harry Henteleff, Mary MacNeil, Paola Marignani, Wojciech Morzycki, Madelaine Plourde, Stephanie Snow, Paola Marcato, Zhaolin Xu
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0251080 (2021)
Most lung cancer patients are diagnosed at an advanced stage, limiting their treatment options with very low response rate. Lung cancer is the most common cause of cancer death worldwide. Therapies that target driver gene mutations (e.g. EGFR, ALK, R
Externí odkaz:
https://doaj.org/article/e3c4b71be1604259a8c3660958c74ff8
Autor:
Marika L Forsythe, Akram Alwithenani, Drew Bethune, Mathieu Castonguay, Arik Drucker, Gordon Flowerdew, Daniel French, John Fris, Wenda Greer, Harry Henteleff, Mary MacNeil, Paola Marignani, Wojciech Morzycki, Madelaine Plourde, Stephanie Snow, Zhaolin Xu
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0236580 (2020)
Lung cancer is generally treated with conventional therapies, including chemotherapy and radiation. These methods, however, are not specific to cancer cells and instead attack every cell present, including normal cells. Personalized therapies provide
Externí odkaz:
https://doaj.org/article/d358aab1202849d2b0953d9c467d7576
Autor:
Hashem O. Alsaab, Alanoud S. Al-Hibs, Rami Alzhrani, Khawlah K. Alrabighi, Aljawharah Alqathama, Akram Alwithenani, Atiah H. Almalki, Yusuf S. Althobaiti
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 4, p 1631 (2021)
Angiogenesis is one of the hallmarks of cancer. Several studies have shown that vascular endothelium growth factor (VEGF) plays a leading role in angiogenesis progression. Antiangiogenic medication has gained substantial recognition and is commonly a
Externí odkaz:
https://doaj.org/article/acdc45fb429943d0a7dd4463fbf24a4e
Autor:
J Fris, Zhaolin Xu, Gordon Flowerdew, Wenda L. Greer, Paola Marcato, Mathieu Castonguay, Drew Bethune, Akram Alwithenani, Paola A. Marignani, Daniel French, Mary MacNeil, Wojciech Morzycki, Madelaine Plourde, Harry Henteleff, Stephanie Snow, Marika Forsythe, Arik Drucker
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 5, p e0251080 (2021)
PLoS ONE, Vol 16, Iss 5, p e0251080 (2021)
Most lung cancer patients are diagnosed at an advanced stage, limiting their treatment options with very low response rate. Lung cancer is the most common cause of cancer death worldwide. Therapies that target driver gene mutations (e.g. EGFR, ALK, R
Autor:
Zhaolin Xu, Stephanie Snow, Marika Forsythe, Gordon Flowerdew, Madelaine Plourde, Wojciech Morzycki, Wenda L. Greer, Harry Henteleff, Arik Drucker, Drew Bethune, Mary MacNeil, Akram Alwithenani, Daniel French, J Fris, Mathieu Castonguay, Paola A. Marignani
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0236580 (2020)
PLoS ONE
PLoS ONE
Lung cancer is generally treated with conventional therapies, including chemotherapy and radiation. These methods, however, are not specific to cancer cells and instead attack every cell present, including normal cells. Personalized therapies provide
Autor:
Wenda L. Greer, Drew Bethune, Harry Henteleff, Wojciech Morzycki, Zhaolin Xu, Stephanie Snow, Marika Forsythe, Akram Alwithenani, Gordon Flowerdew, Michael R. Johnston, Madelaine Plourde, Mary MacNeil, Mathieu Castonguay, A. Surette, Arik Drucker, Daniel French
Publikováno v:
Journal of Thoracic Oncology. 13:S388
Autor:
Wenda L. Greer, Micheal Johnston, Zhaolin Xu, Harry Henteleff, Daniel French, Paola Marcato, Aneil Mujoomdar, Marika Forsythe, Mathieu Castonguay, Gorden Flowerdew, Madelaine Plourde, Akram Alwithenani, Drew Bethune
Publikováno v:
Clinical Cancer Research. 24:B21-B21
Most lung cancer patients are diagnosed at an advanced stage, limiting their treatment options to chemotherapies that have very low response rate. New therapies that target driver gene mutations (e.g., EGFR, ALK, ROS1, BRAF) are being used to treat p